The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

R, Westhovens; D, Yocum; J, Han; A, Berman; I, Strusberg; P, Geusens; MU, Rahman

doi:10.1002/art.21734

Public

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

Shared by NobleBlocks on Apr 1, 2006 • 12:00 AM UTC

Authors:

Westhovens R

Yocum D

Han J

Abstract

<h4>Objective</h4>To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments during 1 year in patients with rheumatoid arthritis (RA) with various comorbidities.<h4>Methods<...

Discussions